792 followers
A phase II study of first-line afatinib for patients aged 26575 years with EGFR mutation-positive advanced ... https://t.co/cEZpqDbeMz
A phase II study of first-line afatinib for patients aged 26575 years with EGFR mutation-positive advanced ... https://t.co/cEZpqDbeMz
A phase II study of first-line afatinib for patients aged 26575 years with EGFR mutation-positive advanced ... https://t.co/cEZpqDsPE7
A phase II study of first-line afatinib for patients aged 26575 years with EGFR mutation-positive advanced ... https://t.co/cEZpqDbeMz
《短報》 【EGFR陽性肺がん:一次治療】75歳以上の日本人37人の「ジオトリフ40mg/日」の治療成績。奏効率 75.7%、PFS 14.2ヵ月、OS 35.2ヵ月。治療関連有害事象のため78.9%が減量、21.1%が治療中止。〔BMC Cancer〕 https://t.co/S27hh0JeI9